Cargando…

Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform

Everolimus-eluting stents (EES) represent the next generation of drug-eluting stents (DES). Important design modifications include thin strut stent backbones, less inflammatory and more biocompatible polymers, and lower drug dosing. The cobalt chromium EES fluoropolymer XIENCE V stent has been the m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Whitbeck, Matthew G., Applegate, Robert J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3733651/ https://www.ncbi.nlm.nih.gov/pubmed/23926441 http://dx.doi.org/10.4137/CMC.S11516

Ejemplares similares

Everolimus-eluting coronary stents
por: Saez, Alejandro, et al.
Publicado: (2010)

Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V(®))
por: Sheiban, Imad, et al.
Publicado: (2008)

Everolimus-eluting stents in interventional cardiology
por: Townsend, Jacob C, et al.
Publicado: (2012)

Is There an Advantage of Ultrathin-Strut Drug-Eluting Stents over Second- and Third-Generation Drug-Eluting Stents?
por: Gherasie, Flavius-Alexandru, et al.
Publicado: (2023)

Safety and Efficacy of Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Second-Generation Drug-Eluting Stents in Real-World Practice
por: Lee, Joo Myung, et al.
Publicado: (2023)

A meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients
por: Ouyang, Hang, et al.
Publicado: (2021)

Mechanical properties of the everolimus-eluting bioresorbable vascular scaffold compared to the metallic everolimus-eluting stent
por: Dalos, Daniel, et al.
Publicado: (2016)

Everolimus-eluting stent platforms in percutaneous coronary intervention: comparative effectiveness and outcomes
por: Panoulas, Vasileios F, et al.
Publicado: (2015)

Everolimus-eluting stents: update on current clinical studies
por: Allocco, Dominic J, et al.
Publicado: (2011)

Everolimus-eluting stents versus sirolimus-eluting stents in patients with cardiac allograft vasculopathy
por: Hawranek, Michał, et al.
Publicado: (2021)

Biodegradable polymer everolimus-eluting stents versus contemporary drug-eluting stents: a systematic review and meta‑analysis
por: Yin, Juntao, et al.
Publicado: (2023)

Stent Fracture after Everolimus-Eluting Stent Implantation
por: Almasood, Ali S., et al.
Publicado: (2011)

Early definite stent thrombosis with everolimus-eluting stents
por: Naito, Ryo, et al.
Publicado: (2015)

Comparison of everolimus-eluting and biolimus-eluting coronary stents with everolimus-eluting bioresorbable scaffold: study protocol of the randomized controlled EVERBIO II trial
por: Arroyo, Diego, et al.
Publicado: (2014)

Multianalysis with optical coherence tomography and vasomotion in everolimus-eluting stents and everolimus-eluting biovascular scaffolds: the MOVES trial
por: Arroyo, Diego A, et al.
Publicado: (2018)

Two-Year Results of an Open-Label Randomized Comparison of Everolimus-Eluting Stents and Sirolimus-Eluting Stents
por: Velders, Matthijs A., et al.
Publicado: (2013)

Next generation drug-eluting stents: focus on bioabsorbable platforms and polymers
por: Doyle, Brendan, et al.
Publicado: (2009)

Clinical results of everolimus-eluting stents and sirolimus-eluting stents in patients undergoing percutaneous coronary intervention
por: Jafaripour, Iraj, et al.
Publicado: (2023)

Everolimus-Eluting Second-Generation Stents for Treatment of De Novo Lesions in Patients with Cardiac Allograft Vasculopathy
por: Pyka, Łukasz, et al.
Publicado: (2020)

Correction: Two-Year Results of an Open-Label Randomized Comparison of Everolimus-Eluting Stents and Sirolimus-Eluting Stents
por: Velders, Matthijs A., et al.
Publicado: (2013)

Clinical outcome of biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with diabetes
por: Kakizaki, Ryota, et al.
Publicado: (2020)

Case series of coronary artery aneurysms after Everolimus eluting stent implantation and comparison with Sirolimus eluting stents
por: Sharma, Raghav, et al.
Publicado: (2022)

Comparison of drug-eluting balloon with repeat drug-eluting stent for recurrent drug-eluting stent in-stent restenosis
por: Wang, Guozhong, et al.
Publicado: (2019)

Conformability in everolimus-eluting bioresorbable scaffolds compared with metal platform coronary stents in long lesions
por: Fam, Jiang Ming, et al.
Publicado: (2017)

Drug-Eluting Balloons versus Second-Generation Drug-Eluting Stents for Treating In-Stent Restenosis in Coronary Heart Disease after PCI: A Meta-Analysis
por: Xiu, Wen-Juan, et al.
Publicado: (2018)

One-Year Outcome of Everolimus-Eluting Stents Versus Biolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention
por: Alidoosti, Mohammad, et al.
Publicado: (2016)

Everolimus-Eluting versus Paclitaxel-Eluting Stents in Percutaneous Coronary Intervention: Meta-Analysis of Randomized Trials
por: Alazzoni, Ashraf, et al.
Publicado: (2012)

Midterm Clinical Impacts of Biodegradable Polymer Everolimus-Eluting Stents Compared with Durable Polymer Everolimus-Eluting Stents: A 3-Year Propensity-Matched Study
por: Matsuda, Hiroaki, et al.
Publicado: (2020)

Genetic risk model for in-stent restenosis of second-and third-generation drug-eluting stents
por: Liu, Yen-Wen, et al.
Publicado: (2021)

Clinical outcomes of biodegradable polymer biolimus-eluting BioMatrix stents versus durable polymer everolimus-eluting Xience stents
por: Lee, Da Hyon, et al.
Publicado: (2017)

Impact of Paclitaxel-Eluting Balloons Compared to Second-Generation Drug-Eluting Stents for of In-Stent Restenosis in a Primarily Acute Coronary Syndrome Population
por: Marquis-Gravel, Guillaume, et al.
Publicado: (2017)

Biodegradable polymer drug-eluting stents versus second-generation drug-eluting stents in patients with and without diabetes mellitus: a single-center study
por: Tang, Xiao-Fang, et al.
Publicado: (2018)

Drug-Eluting Stent: A Review and Update
por: Htay, Thein, et al.
Publicado: (2005)

Coronary Artery Aneurysm after Second-Generation Drug-Eluting Stent Implantation
por: Hong, Sung-Jin, et al.
Publicado: (2019)

Five‐year angiographic, OCT and clinical outcomes of a randomized comparison of everolimus and biolimus‐eluting coronary stents with everolimus‐eluting bioresorbable vascular scaffolds
por: Schukraft, Sara, et al.
Publicado: (2021)

A novel platinum chromium everolimus-eluting stent for the treatment of coronary artery disease
por: Bennett, Johan, et al.
Publicado: (2013)

Effects of Everolimus-Eluting Stents on the Left Ventricular Systolic and Diastolic Functions
por: Parsaee, Mohammad Sadegh, et al.
Publicado: (2015)

Comparison of the everolimus-eluting bioresorbable vascular scaffold versus the everolimus-eluting metallic stent in real-world patients with ST-segment elevation myocardial infarction
por: Desperak, Piotr, et al.
Publicado: (2020)

Biodegradable polymer-coated thin strut sirolimus-eluting stent versus durable polymer-coated everolimus-eluting stent in the diabetic population
por: Gasior, Pawel, et al.
Publicado: (2021)

The everolimus-eluting Xience stent in small vessel disease: bench, clinical, and pathology view
por: Sanchez, Oscar D, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_f9s72lmc5kevob9ppfmuiruapi